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Abstract  
Introduction: cardiovascular risk factors are prevalent in HIV-positive patients which places them at increased risk for cardiovascular disease 
(CVD). We aimed to determine the risk factors and risk assessment for CVD in HIV-positive patients with and without antiretroviral therapy. 
Methods: this was a cross-sectional study of HIV-positive patients attending the Lagos University Teaching Hospital, Nigeria. Anthropometric and 
blood pressure measurements were performed; fasting lipid profile, plasma glucose, homocysteine and hsCRP were determined, as well as 
prevalences and risk assessments. Statistical tests were used to compare the groups and p-value <0.05 was considered to be significant. 
Results: 283 subjects were recruited for this study (100 HIV-positive treatment-naive, 100 HIV-positive treated and 83 HIV negative controls). 
Compared to the controls, mean (sd) values were significantly higher among HIV-treated subjects: waist circumference=88.7 (10.4), p=0.035; 
systolic bp= 124.9 (20.7), p=0.014; glucose= 5.54 (1.7), p=0.015; triglyceride= 2.0 (1.2), p<0.001; homocysteine= 10.9 (8.9-16.2), p=0.0003; 
while hsCRP= 2.9 (1.4-11.6), p=0.002 and HDL-C=0.9 (0.4), p=<0.0001 were higher among the HIV-naïve subjects. Likewise, higher prevalences 
of the risk factors were noted among the HIV-treated subjects except low HDL-C (p<0.001) and hsCRP (p=0.03) which were higher in the HIV-
naïve group. Risk assessment using ratios showed high risk for CVD especially in the HIV-naïve group. The median range for Framingham risk 
assessment was 1.0 - 7.5%. Conclusion: Risk factors and risk assessment for CVD are increased in HIV-positive patients with and without 
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Cardiovascular disease (CVD) is a group of disorders of the heart 
and blood vessels which can manifest as coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, rheumatic heart 
disease, congenital heart disease, deep vein thrombosis and 
pulmonary embolism [1]. It is a primary cause of death worldwide 
[2] with atherosclerosis being the most common pathological 
process that leads to it, involving a combination of vascular 
endothelial dysfunction, chronic inflammation, and dyslipidaemia 
[3]. According to the Global burden of disease study, current 
predictions estimate that by the year 2020, CVD, notably coronary 
heart disease (CHD), will become the leading global cause of total 
disease burden [4]. 
  
Several risk factors for CVD have been identified and can be 
categorized into two groups: Modifiable (by lifestyle and/or 
pharmacotherapy) and Unmodifiable. The traditional risk factors for 
CVD recognized by the current National Cholesterol Education 
Project (NCEP) Adult Treatment Panel III (ATP III) guidelines 
include [3]: age: men ≥45yrs, women ≥55yrs, cigarette smoking, 
hypertension or use of antihypertensive medication, dyslipidaemia, 
diabetes mellitus, obesity, family history of premature CHD in a first 
degree relative male ≤55yrs or female ≤65yrs, and prior CVD in the 
index individual. 
  
In addition, a variety of novel biochemical markers have been 
suggested to identify individuals at increased risk for CVD, such as: 
markers of inflammation e.g. high sensitivity C-reactive protein 
(hsCRP)[5], Homocysteine [6-8], markers of fibrinolytic and 
haemostatic function e.g. tissue type plasminogen activator antigen 
and fibrinogen respectively [9]. 
  
Sub-Saharan Africa is still scourged by the Human 
Immunodeficiency Virus (HIV) infection, and this remains a major 
health concern with a prevalence of 4.9% equating to 23.5 million 
people, of which 874,000 are plagued with infectious diseases such 
as tuberculosis [10]. But with the introduction of highly active 
antiretroviral therapy (HAART),HIV-infected patients are surviving 
AIDS-related causes of death [10]. Unfortunately, this population is 
faced with the new challenge of non-communicable diseases 
because the virus as well as HAART now predisposes them to 
endothelial dysfunction, chronic inflammation, and dyslipidaemia [11 
-13] which are necessary for atherosclerosis that may ultimately 
lead to CVD. 
  
Metabolic abnormalities have been well-described in HIV positive 
patients on HAART especially those on Protease inhibitors. They 
include: hypertriglyceridemia, hypercholesterolemia, lipodystrophy 
and insulin resistance/type2 diabetes mellitus [14, 15], as well as fat 
redistribution, lipoatrophy or fat accumulation [16] referred to as 
HAART-associated morphologic and metabolic abnormality 
syndrome (HAMMAS) or HIV- associated lipodystrophy syndrome 
(HLS) [17]. These features can cause atherosclerotic CVD, therefore 
treated HIV patients may develop cardiovascular complications. 
  
Similarly, untreated HIV positive patients are at risk for CVD. They 
have increased production of pro-inflammatory cytokines e.g. C-
reactive protein, tumour necrosis factor, interleukin 6 (IL-6); with 
concomitant decrease in anti-inflammatory cytokines e.g. IL-10, 
adiponectin; which promotes endothelial activation and chronic 
inflammation [11, 12]. These are pathophysiological factors in the 
development of CVD. These cytokines can also have effects on 
different enzymes of lipid metabolism resulting in dyslipidaemia 
[13], a major CVD risk factor. Therefore, it is important to identify 
CVD risk factors and conduct risk assessments bearing in mind the 
differences in the aetiological processes of CVD among treated and 
untreated HIV positive patients. The outcome will be beneficial in 
prompting early intervention. The aim of this study was to 
determine the risk factors and assessment for CVD among HIV-







This was a cross-sectional study of cardiovascular disease risk 
factors in HIV-positive adult patients attending the HIV outpatient 
clinic of the Lagos University Teaching Hospital (LUTH), which is a 
tertiary hospital in Lagos, Southwest Nigeria. The study protocol 
was reviewed and approved by the Hospital’s Research and Ethics 




Male and female adult patients aged 21 to 60 years with confirmed 
HIV seropositivity by double enzyme linked immunosorbent assay 
(ELISA) and confirmatory Western blot were included as the 
subjects in the study. The sampling technique was by stratified, 
random sampling, where stratification was by whether patients had 
been taking antiretroviral therapy for over one year or not at all. 
Patients were randomly selected using a table of random numbers. 
Those with CD4+ T cell counts ≥350cells/mm3 and who had not 
received HAART were designated as the ‘naive’ group, while 
patients who had commenced HAART for at least six months were 
designated the ‘treated’ group. 
  
Considering that there are several CVD risk factors with their 
respective prevalence rates [7, 18] the sample size was not 
calculated using the formula: n = z2pq/d2 where n = sample size, z= 
critical value at 95% confidence level, usually set at 1.96, p= 
Prevalence, q= 1-p, d= precision of 5% (0.05) [19]. Literature 
review showed that the sample size of 171 was used in a similar 
study [18]. 
  
But to increase the validity of our study, anextra 17% were included 
to cater for non-responders, giving a sample size of 200 for the 
subject cases. The controls were age and sex-matched adult HIV 
negative participants recruited during community outreaches after 
voluntary counseling and testing. They were included in acase: 
control ratio of 2:1; however some controls were lost to follow up. 
Patients with secondary causes of dyslipidaemia and hyperglycaemia 
were excluded, including pregnant women and nursing mothers. 
Participants were recruited for the study after they were fully 




Questionnaires were administered to the subjects to obtain basic 
demographic data and history of: HAART use- type and duration, 
cigarette smoking, antihypertensive and diabetic medication use. 
Thereafter, blood pressure was taken in the sitting position after 
five minutes of rest using a digital sphygmanometer. Weight in 
kilograms (kg) was measured to the nearest 0.1kg using a 
calibrated measuring scale, while height in metres (m) was 
measured to nearest 0.1m using a calibrated stadiometerfor the 
calculation of body mass index (BMI= weight/ (height)2, Waist 
circumference (WC) in centimetres (cm) was measured to the 
nearest 0.1cm using a tape rule at midway between the subcostal 
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plane and the iliac crest. Hip circumference (HC) was also measured 
at the largest width and used to calculate the waist-to-hip ratio 




The participants were requested to return in the morning after an 
overnight 10-12hr fast when antecubital venous blood collection 
was performed. Five mls of blood was drawn into a plain vacutainer 
for lipid profile and hsCRP; 3mls into a fluoride oxalate vacutainer 
for glucose assay and 3mls into an EDTA vacutainer for 
homocysteine determination. The specimens were taken to the 
laboratory where they were centrifuged at 4000rpm for 10minutes. 
The supernatant, plasma or serum as the case may be, was 
separated out. The fluoride oxalate plasma was analyzed for glucose 
daily. While the EDTA plasma was aliquoted into a cryogenic storage 
tube for homocysteine, also the serum was aliquoted into two 
cryogenic storage tubes (one for lipid profile and hsCRP each) and 
stored at -70°C in a well-monitored freezer (NuAire, USA), for one 
month until the analyses were performed. Haemolysed, icteric and 
lipaemic samples were excluded. 
  
Biochemical analysis Glucose oxidase method was used to 
estimate fasting plasma glucose concentration, Total cholesterol 
(TC), Triglyceride (TG) and High Density Lipoprotein-Cholesterol 
(HDL-C) were analyzed with standard enzymatic methods, while 
Low Density Lipoprotein-Cholesterol (LDL-C) was determined by a 
direct, homogenous assay on a Roche Hitachi 902 analyzer (Roche 
diagnostics, Germany). The LDL-C method was employed to 
circumvent the limitation of the routinely used Friedewald equation 
[20], which cannot be applied when TG >400mg/dl,as this may be 
seen in HIV patients on HAART. A sandwich, solid-phase ELISA was 
used to determine hsCRP concentrations (Diagnostic Automation 
Inc.,USA), as well as homocysteine (Axis Shield, Germany) and read 





Precision studies were carried out for the lipids and glucose using 
bovine precision sera (RANDOX, UK) level 2 (lot no 407SN, expiry 
date 2014/03) and level 3(lot no 324SE, expiry date 2013/04); and 
coefficient of variation (%CV) was calculated for within and between 
assay runs. Liquichek liquid control (BIORAD, UK) medium level was 
used to control the hsCRP assay(lot no 0906296, expiry date 2012-
10), while a tri-level control set (Axis Shield, Germany) was used to 





Data from the completed questionnaires and laboratory results were 
categorized into: Subjects (HIV-positive naive, HIV-positive treated) 
and Controls (HIV negative). They were entered unto a spreadsheet 
(Microsoft Office Excel 2007) where BMI and CVD risk ratios were 
calculated. Ten-year risk assessment for CVD was performed using 
Framingham risk score calculator [21]. Statistical analyses were 
performed using SPSS version 20 (Chicago IL, USA). Kolmogorov-
Smirnov test was used to test for normality and results for hsCRP 
and homocysteine were log-transformed. One-way ANOVA was used 
to compare the mean values between the three subgroups, while 
the Student’s t-test was used for comparison of mean of continuous 
variables between the controls and each subject subgroup to 
distinguish their individual contributing differences .Prevalence and 
95% confidence intervalsof high risk factors for CVD were 
performed. Z-test was performed to compare prevalences between 
the naïve and treated subjects. The level of statistical significance 





Two hundred and eighty-three (283) participants consisting of 170 
(60%) females and 113(40%) males were included in this study. 
The HIV naïve patients were 100 with mean ± sd age of 35.6 ± 
8.1years, the HIV treated patients were 100 with mean ± sd age of 
37.5± 7.8years, and the age- and sex-matched HIV negative 
controls were 83 with mean ± sd age of 36.6 ± 7.2 yrs. Of the 
treated patients, eighty-five (85) had been administered NRTI-
based therapy, while 15 received PI-based regimen. 
  
The mean values of CVD risk factor variables are shown in Table 
1 highlighting significant differences between the 3 groups, while 
in Table 2 the means were compared between the controls and 
each subject subgroup. The prevalence of risk factor variables using 
cut off levels of high risk for CVD are shown in Table 3. 
  
Risk assessment for CVD using Grover’s risk ratio LDL-C/HDL-C [22] 
revealed mean ± sd of HIV naïve 3.6 ± 2.5 and HIV treated 2.5 ± 
1.4 which fall in the range of 3.3 – 3.7 that signifies increased risk 
of death from CVD [23]. Similarly, TC/HDL-C [22] showed mean ± 
sd of HIV naïve 5.9 ± 3.7 and HIV treated 4.8 ± 5.2 which are >5.6 
that signifies high risk for CVD [24]. Atherogenic Index (log 
TG/HDL-C) [25] showed mean ± sd of HIV naïve +0.18 ± 0.3 and 
HIV treated -0.03 ± 0.4, where the more positive the ratio, the 
higher the risk for CVD, and vice versa [26]. 
  
Ten year risk assessment for CVD using Framingham risk score 
performed on patients that had ≥2 risk factors showed median 
(interquartile range) of HIV naïve women n=6, 1.5% (1 - 3.75%); 
HIV naïve men n= 9, 6.5% (2 - 11.25%); HIV treated women 
n=16, 1.0% (1.0 - 4.5%);and HIV treated men n=18, 7.5% (4.25 - 
16.5%).Three patient data sets were excluded because they 
exceeded the equation variables’ limits (age=20 – 99years, TC= 130 






In this study, the major independent risk factors for CVD were 
identified in the HIV positive patients, although their mean values 
were not exceptionally elevated as similarly reported by Oduola et al 
[27]. Despite this, measures of obesity (WC, WHR), diabetes 
mellitus (fasting plasma glucose), hypertension (systolic blood 
pressure), dyslipidaemia (hypertriglyceridaemia, low HDL-C), hsCRP, 
and homocysteine in the subjects were significantly higher than the 
HIV negative controls. 
  
High TG with low HDL-C in HIV naïve subjects compared to the HIV 
negative controls was demonstrated by Rose et al [28]. This 
corroborates our findings and may suggest that HIV infection is 
associated with modified HDL metabolism re-directing cholesterol to 
the apo B-containing lipoprotein and likely reduces the functionality 
of reverse cholesterol transport [29]. Also, the presence of 
endothelial lipase and phospholipase A2 during the vascular 
inflammation induced by the viral infection results in low HDL-C 
[30], therefore a dyslipidaemic pattern is associated with HIV 
infection itself. On the other hand, the metabolic changes we 
observed in the HIV-treated patients were in line with the features 
of HAMMAS, with women having greater prevalence of obesity. 
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The prevalence of dyslipidaemia among HIV treated subjects 
observed in another Nigerian study were lower than ours except 
hypertriglyceridaemia. Theirs revealed hypercholesterolaemia 
=28%, elevated LDL-C= 24% and hypertriglyceridaemia =35%, 
using desirable cut-off values of TC-200mg/dl (5.2mmol/L), LDL-C-
130mg/dl (3.3mmol/L), TG-150mg/dl (1.7mmol/L) respectively 
[31]. The difference to our finding of hypertriglyceridaemia = 24% 
may be explained by the specific HAART medication the patients 
may be taking. 
  
Protease inhibitors (PIs) are antiretroviral drugs that target the 
catalytic region of HIV protease and prevent it from cleaving 
translated precursor polyprotein to individual proteins in order to 
form mature viral particles, resulting in non-infectious viral particles. 
However, this region is homologous with regions of two human 
proteins that regulate lipid metabolism: cytoplasmic retinoic-acid 
binding protein-1 (CRABP-1) and low density lipoprotein-receptor-
related protein (LRP) [16], which would result in increased 
apoptosis of peripheral adipocytes, decreased pre-adipocyte 
differentiation, decreased triglyceride storage in adipose tissue, 
increased VLDL production, impaired hepatic chylomicron uptake 
and endothelial triglyceride clearance, resulting in 
hypertriglyceridaemia [16,32]. 
  
Although patients on nucleoside reverse transcriptase inhibitors 
(NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) 
may develop lipodystrophy, insulin resistance, high TC and LDL-C, 
only modest elevations in TG have been described [33,34]. The 
increased prevalence of hypertriglyceridaemia in HIV patients 
treated with PI versus the NRTI was also demonstrated in a study 
by Salami et al [35]. In our study, only 15 HIV treated patients were 
on PIs because it is second-line medication, administered when the 
NRTI-based regimen fails [36]. Higher mean hsCRP concentration 
and prevalence were observed in the HIV naïve subjects when 
compared to treated patients and the controls (p <0.001), similar to 
reports from other studies [37,38]. This could be due to the 
unhindered chronic inflammation by the viral infection in these 
subjects which may be alleviated with HAART and antioxidants. 
  
Plasma Homocysteine concentrations were significantly elevated in 
both naive and treated HIV subjects than the controls, corroborating 
findings in other studies [39,40]. We demonstrated 
hyperhomocysteinaemia prevalence of HIV naïve= 35% and HIV 
treated=39%; which were higher than what was observed in a 
study conducted in Italy, where the HIV treated prevalence was 
28.3%, using the same cut-off value of > 12µmol/L [41]. This may 
be due to the reduced intake of folic acid, vitamin B6 and vitamin 
B12 supplements in our African population which are required for 




It is recommended to examine for CVD traditional risk factors in 
adults 20 -79 years of age who are free of atherosclerotic CVD in a 
bid to assess their risk for future coronary heart disease [3]. 
Absolute cutoff values have been assigned for each risk factor 
(Table 3) which give an indication of high risk for CVD. 
  
Although quantitative measurements of the lipid profile can be used 
to ascribe risk and target treatment strategies [3], Gotto et al claim 
that that approach is more helpful for extreme values and not for 
marginal values [42] like those seen in our subjects. The thirty-
person/ten-country study recommends using apoB/apoA1 ratio to 
evaluate lipoprotein risk for CVD [43], but a more readily available 
correlate would be LDL-C/HDL-C which has proven to be the best 
lipid-related predictor of future cardiovascular event [22, 44] than 
LDL-C or HDL-C alone [45]. Unfortunately, these ratios have not 
been validated in HIV-infected populations and may be limited 
because it excludes TG which is a common feature in them, 
especially those on HAART. Therefore, atherogenic index (AI) which 
is derived from log10 of serum (TG/HDL-C) and has been shown to 
be a surrogate of small, dense LDL particle size that predicts 
coronary artery disease independently, as well as type 2 diabetes 
mellitus, high blood pressure and metabolic syndrome [25] may be 
useful. 
  
Using these risk indices, we observed an increased risk for CVD, 
which was exaggerated in the HIV naïve group, corroborated by a 
study conducted in India [46]. Similarly, a study conducted in 
Uganda demonstrated increased TC/HDL-C ratio in the HIV naïve 
(4.6) versus the HIV treated (3.4) [47]. These findings are 
attributed to the relatively lower HDL-C levels, which have also been 
independently associated with increased CVD risk [3]. 
  
Although published guidelines do not recommend measurement of 
any of the emerging novel risk factors for the purpose of routine 
evaluation [48], nor for risk assessment [3]; hsCRP ≥ 2mg/L can be 
applied to revise risk assessment upward when risk-based treatment 
decisions are uncertain after quantitative risk assessments [48]. 
Similarly, in a meta-analysis of the association between 
homocysteine and CVD, it was found that for every 5umol/L 
increase in serum homocysteine concentration, the risk of ischaemic 
heart disease increased 20% to 30% [49]. Thus, clinically, the 
measurement of total homocysteine is considered important as a 
risk factor for CVD and other disorders [9, 50, 51]. 
  
The Framingham risk-assessment tool is a coronary prediction 
algorithm that provides estimates of total CHD risk (risk of 
developing one of the following: angina pectoris, myocardial 
infarction, or coronary disease death) over the course of 10 years 
[52]. It is used for individuals in the general population who have 
two or more risk factors for CVD. The factors used to estimate risk 
include: age, gender, TC, HDL-C, systolic blood pressure and 
antihypertensive medication, and cigarette smoking. Relative risk for 
CHD is estimated by comparison to low risk Framingham 
participants, and standard practice is to initiate some form of 
intervention when the 10-year Framingham risk exceeds 20% [52]. 
Our subjects had a median range of 1.0 - 7.5%. Limitations in the 
use of the Framingham tool for HIV-infected patients include: 
underestimation of cardiovascular events because key factors such 
as hypertriglyceridemia, are not used in the Framingham 
calculations. Also, there are direct effects of HIV and HAART on CVD 
risk that are not captured in the calculations [52]. Based on these, 
Law et al suggest that lower 10-year CVD risk calculations should be 
used to guide CVD interventions among HIV-treated patients than 
those used for the general population [53]. If this is adopted, 
maybe our subjects risk scores would fall within adverse ranges. 
  
The cross-sectional design of this study was a limitation because a 
prospective study of HIV patients followed up after commencement 
of HAART would have enabled us to monitor their distinct metabolic 
changes. Also the Framingham risk calculator could not compute 





Considering the high prevalence of CVD risk factors in both the HIV 
naïve and HIV treated subjects observed in this study, it would be 
difficult to identify which patients are at risk for CVD simply from 
their HIV status or their antiretroviral therapy alone. It is suggested 
that regular biochemical examination of the cardiovascular system in 
all HIV-infected patients be performed to prevent atherosclerotic 
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vascular complications and to reduce the risk for future 
cardiovascular events. 
 
What is known about this topic 
 
• CVD is a leading cause of morbidity and mortality globally; 
• Increasing prevalence of CVD risk factors predisposes the 
population to CVD; 
• HAART use predisposes HIV treated patients to develop 
CVD risk factors. 
 
What this study adds 
 
• The HIV virus itself predisposes untreated positive 
patients to develop CVD risk factors as well; 
• Risk assessment of both naïve and treated HIV positive 
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Table 1: Comparison of the mean values of CVD risk factors in 
subjects and controls  
Table 2: Comparison of mean values of CVD risk factors of each 
subject subgroup versus controls  
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Table 2: comparison of mean values of CVD risk factors of each subject subgroup versus controls 
Modifiable 
ASCVD risk factor 
Parameter 
HIV naïve (n = 100) 
Mean ± sd 
T-test 
p-valueγ 
HIV treated (n = 
100) 
Mean ± sd 
T-test 
p-valueγ 
Controls (n =83) 
Mean ± sd 
Obesity BMI (kg/m2) 25.6 ± 5.3 0.78 25.5± 4.5 0.88 25.3± 5.9 
  Waist Circumference 
(cm)           
  Women 87.7± 9.9 0.06 88.7 ± 10.4 0.035+ 81.9± 17.6 
  Men 86.3 ± 13.9 0.89 88.9± 13.0 0.55 86.8 ± 5.9 
  Waist-to-Hip Ratio           
  Women 0.83 ± 0.05 0.67 0.87± 0.07 0.005+ 0.82± 0.07 
  Men 0.87 ± 0.07 0.89 0.88 ± 0.06 0.83 0.87± 0.05 
Hypertension SBP (mmHg) 121.5 ± 20.7 0.11 124.9± 20.7 0.014+ 114.8± 11.7 
  DBP (mmHg) 73.8 ± 12.8 0.74 75.4± 13.9 0.38 72.9± 10.7 
Diabetes mellitus Glucose (mmol/L) 4.9 ± 1.6 0.50 5.54 ± 1.7 0.015+ 4.7 ± 1.7 
Dyslipidaemia TC (mmol/L) 4.7 ± 1.4 0.30 5.5± 1.4 0.05 5.1± 1.10 
  TG (mmol/L) 1.4± 0.7 0.019+ 2.0± 1.2 <0.0001+ 1.1± 0.6 
  LDL-C (mmol/L) 3.1± 1.2 0.29 3.3± 1.2 0.20 3.3± 1.1 
  HDL-C (mmol/L) 0.9± 0.4 <0.0001+ 1.5± 0.6 0.48 1.4± 0.3 
Inflammation hsCRP (mg/L)§ 2.9 (1.4 – 11.6) 0.002+ 1.9 (1.3 – 2.2) 0.95 2.2 (0.8 – 4.5) 
Atherothrombosis Homocysteine (umol/L)§ 10.9 (8.5 – 13.6) 0.001+ 10.9 (8.9 – 16.2) 0.0003+ 16.3 (13.3 – 20.7) 









Table 1: comparison of the mean values of CVD risk factors in subjects and controls 
Modifiable ASCVD 
risk factor 
parameter HIV naïve (n = 
100) 
Mean ± sd 
HIV treated (n = 100) 
Mean ± sd 
Controls (n =83) 




Obesity BMI (kg/m2) 25.6 ± 5.3 25.5± 4.5 25.3± 5.9 0.93 
  Waist Circumference 
(cm)         
  Women 87.7± 9.9 88.7 ± 10.4 81.9± 17.6 0.001+ 
  Men 86.3 ± 13.9 88.9± 13.0 86.8 ± 5.9 0.26 
  Waist-to-Hip Ratio         
  Women 0.83 ± 0.05 0.87± 0.07 0.82± 0.07 <0.001+ 
  Men 0.87 ± 0.07 0.88 ± 0.06 0.87± 0.05 0.42 
Hypertension SBP (mmHg) 121.5 ± 20.7 124.9± 20.7 114.8± 11.7 0.001+ 
  DBP (mmHg) 73.8 ± 12.8 75.4± 13.9 72.9± 10.7 0.40 
Diabetes mellitus Glucose (mmol/L) 4.9 ± 1.6 5.54 ± 1.7 4.7 ± 1.7 0.002+ 
Dyslipidaemia TC (mmol/L) 4.7 ± 1.4 5.5± 1.4 5.1± 1.10 <0.001+ 
  TG (mmol/L) 1.4± 0.7 2.0± 1.2 1.1± 0.6 <0.001+ 
  LDL-C (mmol/L) 3.1± 1.2 3.3± 1.2 3.3± 1.1 0.39 
  HDL-C (mmol/L) 0.9± 0.4 1.5± 0.6 1.4± 0.3 <0.001+ 
Inflammation hsCRP (mg/L)§ 2.9 (1.4 – 11.6) 1.9 (1.3 – 2.2) 2.2 (0.8 – 4.5) <0.001+ 
Atherothrombosis Homocysteine (umol/L)§ 10.9 (8.5 – 13.6) 10.9 (8.9 – 16.2) 16.3 (13.3 – 20.7) <0.001+ 
+statistically significantat <0.05,  § median (interquartile range)     
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Table 3: comparison of prevalence of high risk factors for CVD in HIV subjects 
Modifiable ASCVD 
risk factor Parameter 
Cutoff level 
for CVD risk 
HIV naïve (n = 100) 
Prevalence%  (95% 
CI) 
HIV treated  (n=100) 





Body Mass Index ≥ 30kg/m2 13%  (7 – 19%) 17%  (10 – 25%) 0.43 
Waist Circumference         
Women > 88cm 18%  (11 – 25%) 27%  (19 – 34%) 0.13 
  Men > 102cm 6%  (2 – 11%) 9%  (4 – 15%) 0.42 
  Waist-to-Hip Ratio         
  Women > 0.85 26%  (18 – 34%) 28%  (20 – 35%) 0.75 
  Men > 0.9 13 %  (7 – 19%) 15%  (9 – 20%) 0.68 
Hypertension Systolic BP > 140 mmHg 12%  (6 – 19%) 23%  (15 – 31%) 0.04+ 
  Diastolic BP > 90 mmHg 11%  (6 – 19%) 20%  (11 – 28%) 0.08 
Diabetes mellitus Glucose > 7.0mmol/L 2%  (1 – 4%) 9%  (4 – 16%) 0.03+ 
Dyslipidaemia Total Cholesterol ≥ 5.2mmol/L 34% (26 – 43%) 47%  (38 – 55%) 0.06 
  Triglyceride ≥ 1.7mmol/L 21%  (14 – 29%) 24%  (15 – 32%) 0.61 
  LDL-C ≥ 3.3mmol/L 30%  (22  – 39%) 37%  (28 – 46%) 0.29 
  HDL-C < 1.0 mmol/L 42%  (33 – 50%) 11%  (5 – 17%) <0.001+ 
Inflammation hsCRP ≥ 2 mg/L 51%  (42 – 59%) 36%  (27 – 46%) 0.03+ 
Atherothrombosis Homocysteine > 12 umol/L 35%  (26 – 44%) 39%  (29 – 49%) 0.56 
+statistically significant at  <0.05 
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